The tumor that happens there starts prohibiting the normal function of the gland and triggers imbalance in the secretion of hormone that causes adverse effects on the body. A large number of growths are benign and can be classed as adenomas.
The global pituitary cancer market is showing growth opportunities at a 9.4% CAGR in the years between 2017 and 2023, which has been defined by Market Research Future (MRFR) as the forecast period. Pituitary cancer can be described as a medical condition that displays an abnormal growth in the pituitary gland.
However, pituitary cancer is quite strange in its behavior as it does not spread to other parts of the body. Growing number of cases getting registered, better financial growth in the market, high integration of various strategies launched by major market players, contribution of researchers, technological advancements, and others are expected to function in dynamic ways to provide the market ample growth opportunities. The high number of geriatric populations getting affected by the disease, high disposable income to avail facilities, better FDA workflow, and others are expected to promote the global market for pituitary cancer.
The global market for pituitary cancer can be segmented by diagnosis, treatment type, and end-user. These segments hold records regarding factors that can promote the market in the coming years.
By diagnosis, the market for pituitary cancer can be segmented into urine test, blood tests, vision testing, brain imaging, and others.
By treatment type, the market for pituitary cancer can be segmented into medications, radiation therapy, surgery, and others. The surgery segment includes endoscopic trans-sphenoidal surgery, craniotomy, and others. The radiation therapy segment comprises , proton beam therapy, external beam radiation, gamma knife stereotactic radiosurgeryand others. The medications segment includes bromocriptine, cabergoline, and others.
By end-user, the market for pituitary cancer can be segmented into clinics, hospitals, research institutes, diagnostic centers, and others.
The Americas has the largest market share for the global pituitary cancer market. The growth can be attributed to the increasing demand generated by a well-developed healthcare sector and constantly incoming investment to promote better research and development projects. Researchers are getting support from the government and are leveraging the infrastructural superiority that this region offers. Major countries like the US and Canada are going to promote the market. In the Southern region, the market is getting support from Argentina and Brazil where significant changes are taking place.
Europe has the second-best market position and it can gain notable traction from features that are quite similar to that of North America. Countries like the UK, Spain, Italy, Germany, France, and others can provide thrust to the growth. Increasing expenditure in the research and development sector can promote the regional market further. The Asia Pacific market has the potential to make sure that the regional market gains the fastest speed. This can be attributed to the increasing patient population in the region, better healthcare facilities, increasing government support, and others. Growing awareness regarding the symptoms is also providing traction to the global market.
Eminent players in the global pituitary cancer market are Salzman International (U.S.), Trinity Biotech (Ireland), Sigma-Aldrich Co. LLC (U.S.), Genentech, Inc. (U.S.), Elekta AB (Sweden), Varian Medical Systems, Inc. (U.S.), Ion Beam Applications (Belgium), Accuray Incorporated (U.S.), C. R. Bard, Inc. (U.S.), Nordion, Inc. (Canada), RaySearch Laboratories (Sweden), Isoray Medical, Inc. (U.S.), Mitsubishi Electric Corporation (Japan), Mevion Medical Systems, Inc. (U.S.), and others.